![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C52H72GdN5O14 |
Molar mass | 1148.42 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases. [1]
On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc. [2]
In December 2007, the FDA issued a not approvable letter for motexafin gadolinium. [3]